Application of clostridium butyricum and condensate bacillus in the preparation of medicament for treating inflammatory bowel disease

A technology of bacillus coagulans and inflammatory bowel disease, applied in the field of biopharmaceuticals, can solve problems such as low curative effect, secondary infection, and large adverse reactions, so as to enhance mucosal immune function, prevent inflammation recurrence, and improve disease resistance Effect

Inactive Publication Date: 2008-03-12
QINGDAO EASTSEA PHARMA +1
View PDF0 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The traditional treatment drugs for IBD include aminosalicylic acid, antibiotics and corticosteroids, etc. Because of their low curative effect and large adverse reactions, patients often cannot tolerate them, resulting in certain limitations in clinical application.
The application of immunosuppressants such as azathioprine (AZA), 6-mercaptopurine (6-MP), methotrexate (MTX) and cyclosporine can make most IBD patients, especially intractable cases, obtain a certain degree of clinical However, these immunosuppressants still have the disadvantages of high toxicity, poor selectivity, and the possibility of secondary infection and teratogenicity, so the clinical application is still not ideal

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

preparation Embodiment 1

[0019] Medicine preparation embodiment 1, Clostridium butyricum viable bacteria powder preparation:

[0020] Take a tube of Clostridium butyricum viable strain, dissolve it in a sterilized 100ml Erlenmeyer flask filled with 10ml normal saline and glass beads, activate for 10 minutes, use a 1ml sterile pipette to draw 1ml of the bacterial suspension to inoculate a 50ml expansion flask In a 250ml Erlenmeyer flask with a growth medium, place it in a rocking bed at 37°C for 24 hours with constant temperature oscillation (190rpm), transfer to a 2500ml baffle Erlenmeyer flask with 450ml expansion medium, and culture for 24 hours with constant temperature oscillation at 37°C. Transfer to a seed tank with 4.5L of expansion medium after no bacteria, anaerobic culture (aeration volume 3:1) for 24 hours, and transfer to a fermenter with 45L of fermentation medium after microscopic examination without bacteria In the medium, 37 ℃ anaerobic culture for 24 hours, the microscopic examination...

preparation Embodiment 2

[0021] Medicine Preparation Example 2, Clostridium butyricum Live Bacteria Capsule Preparation

[0022] Composition % (weight)

[0023] Clostridium butyricum live bacteria powder 20.00 parts

[0024] Microcrystalline cellulose 40.00 parts

[0025] Glucose 40.00 parts

[0026] Fully mix the above-mentioned components in groups 1 to 3, and then use conventional filling capsule technology to make capsules according to unit doses.

experiment example 1

[0027] Basic experiment example 1. Therapeutic effects of Clostridium butyricum and Bacillus coagulans on inflammatory bowel disease in immune rats

[0028] 1 Experimental materials and methods

[0029] 1.1 Experimental animals: male SD rats, 180-220g, purchased from Weitong Lihua Experimental Animal Center, clean grade, certificate number: SCXP (Beijing) (2002)-0003.

[0030] 1.2 Experimental drugs: mesalamine (200mg / ml); Clostridium butyricum (CGMCC No.0313.1 strain, 10 8 CFU / ml), Bacillus coagulans (CGMCC No.1207 strain, 10 8CFU / ml) was provided by Qingdao Donghai Pharmaceutical Co., Ltd.

[0031] 1.3 Experimental reagents: Freund's complete adjuvant (sigma), MTT (sigma), concanavalin (ConA) (Sigma); lipopolysaccharide (LPS) (Sigma); MTT (Sigma), purchased from Beijing Shubowei Chemical Industry Instrument Co., Ltd.; 1640 culture medium (Gibco); lyophilized powder of bovine colonic mucosal protein (self-made); IL-8 ELISA kit (BD); TNFα ELISA kit (Ebioscience); rat IgG re...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention discloses a new medicine purpose of Clostridium butyricum and Bacillus coagulans, in particular relates to an application of Clostridium butyricum and Bacillus coagulans in preparing the medicine for curing inflammatory bowel diseases. The inflammatory bowel disease refers to an ulcerative colitis and a Crohn disease. The Clostridium butyricum is selected from but not limited to Clostridium butyricum, CGMCC and the preservation number is 0313.1; the Bacillus coagulans is selected from but not limited to Bacillus coagulans, CGMCC and the preservation number is 1270. The Clostridium butyricum and Bacillus coagulans as a single pharmaceutical active ingredient or a combined pharmaceutical active ingredient has significant curative effect on ulcerative colitis and Crohn's disease, pertaining to the art of biological medicine.

Description

technical field [0001] The present invention relates to the new application of Clostridium butyricum and Bacillus coagulans, in particular to Clostridium butyricum and Bacillus coagulans alone or in combination as active ingredients in the preparation of medicines for treating inflammatory bowel disease, i.e. ulcerative colitis and Crohn's disease The application in the invention belongs to the field of biopharmaceuticals. Background technique [0002] Inflammatory bowel disease (IBD) is a general term for ulcerative colitis (UC) and Crohn's disease (CD), and traditional medicine believes that the cause is unknown. Ulcerative colitis is a non-specific chronic colitis. The lesions are mainly limited to the mucosa and submucosa of the colon. Colon, clinically manifested as persistent or recurrent mucus and bloody stools accompanied by abdominal pain, may have different degrees of systemic symptoms, such as joints, skin, eyes, mouth, liver and gallbladder and other extraintest...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/74A61K9/08A61K9/10A61K9/14A61K9/20A61K9/48A61P1/00A61P1/04A61K35/742
Inventor 崔云龙
Owner QINGDAO EASTSEA PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap